Edition:
United Kingdom

Immune Design Corp (IMDZ.OQ)

IMDZ.OQ on NASDAQ Stock Exchange Global Market

3.65USD
19 Apr 2018
Change (% chg)

$-0.22 (-5.81%)
Prev Close
$3.88
Open
$3.85
Day's High
$3.85
Day's Low
$3.65
Volume
24,531
Avg. Vol
77,446
52-wk High
$13.00
52-wk Low
$2.80

Chart for

About

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. The Company has engineered its technologies to activate the immune system's natural ability to create tumor-specific cytotoxic T cells (CTLs) to... (more)

Overall

Beta: --
Market Cap(Mil.): $269.01
Shares Outstanding(Mil.): 25.62
Dividend: --
Yield (%): --

Financials

  IMDZ.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -2.20 -- --
ROI: -66.38 1.58 14.38
ROE: -66.44 2.41 16.07

BRIEF-Immune Design Reports Q4 Loss Per Share $0.29

* IMMUNE DESIGN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

14 Mar 2018

BRIEF-Immune Design Reports Data Update For Lead Immunotherapy Programs

* IMMUNE DESIGN REPORTS DATA UPDATE FOR LEAD IMMUNOTHERAPY PROGRAMS: IMPROVEMENT IN SURVIVAL FOR CMB305 MONOTHERAPY IN SARCOMA AND INCREASED OBJECTIVE RESPONSES FOR G100/PEMBROLIZUMAB COMBINATION IN FOLLICULAR LYMPHOMA

12 Mar 2018

BRIEF-Immune Design To Report Q4 And Year End 2017 Financial Results And Provide Corporate Update

* IMMUNE DESIGN TO REPORT FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE Source text for Eikon: Further company coverage:

07 Mar 2018

BRIEF-Ecor1 Capital reports 7.4% passive stake in Immune Design

* Ecor1 Capital Llc reports 7.4% passive stake in Immune Design Corp as of Oct 25 - SEC filing‍​ Source text: (http://bit.ly/2zkI4Ki) Further company coverage:

06 Nov 2017

BRIEF-Immune Design reports Q3 loss per share of $0.52

* IMMUNE DESIGN REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

01 Nov 2017

BRIEF-Immune Design prices offering of 19.5 million shares at $4.10 per share​

* Immune Design prices $80.0 million public offering of common stock

25 Oct 2017

BRIEF-Immune Design proposes public offering of common stock

* Immune Design announces proposed public offering of common stock

23 Oct 2017

Earnings vs. Estimates